HitGen is a biotechnology company specializing in innovative drug discovery using DNA-encoded library (DEL) technology. The company operates in the pharmaceutical and biotechnology markets, focusing on creating novel molecules for hit identification and lead generation. HitGen's primary clients include pharmaceutical companies and research institutions seeking to develop new treatments for diseases such as oncology, cardiovascular diseases (CVD), inflammation, respiratory conditions, metabolism disorders, and ophthalmology. The business model revolves around collaborative projects, licensing agreements, and proprietary research initiatives. HitGen generates revenue through partnerships, licensing fees, and milestone payments from successful drug development projects. The company has a robust pipeline with over 20 internal projects, including several in advanced stages of development.

Keywords: DNA-encoded libraries, drug discovery, oncology, cardiovascular diseases, inflammation, respiratory, metabolism, ophthalmology, biotechnology, pharmaceutical.